BAXTER INTERNATIONAL INC
BAX · Healthcare · $11.6B mkt cap · FY2025 filings · No moat ·
Doesn't clear the bar
The four filters
Median gross margin 39.7% over 10y, stable.
Median ROIC 7.1%, above the 9% hurdle in 50% of years.
Net debt/EBITDA 11.2x, interest coverage -1x.
Owner earnings trend unclear, share count shrinking (buybacks).
Margin of safety
- Owner earnings (normalized)
- —
- Est. intrinsic value / share
- —
- Recent price
- $22.61
- Discount to value
- No price data
Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).
20 years of fundamentals
The business, in plain English
BAXTER INTERNATIONAL INC booked $11.2B of revenue in FY2025 in the Healthcare sector and kept 30.1% of it as gross profit — a moderate-margin business by that measure. After every other cost, −8.5% of each revenue dollar reached the bottom line.
Across the filed record, revenue held roughly flat, from $11.3B (FY2007) to $11.2B (FY2025) — about −0.0% a year compounded over 18 years.
It earned −1.8% on invested capital in FY2025, with a median of 4.3% across 13 filed years. The Returns on Capital filter above scores it 27/100.
The balance sheet carried $9.5B of total debt in FY2025. Balance-Sheet Safety scores it 0/100.
The share count fell 14.6% between FY2009 and FY2025 — management has been retiring shares, which concentrates each remaining owner's claim. Capital Discipline scores it 53/100.
Put together: Pricing Power is the strongest of the four filters (61/100) and Balance-Sheet Safety the weakest (0/100), which is how BAX lands at 37/100 — a None moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Gaps in a line mean that item isn’t in BAX’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.
Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars
None yet — BAX has read No moat for every logged capture since Jul 17, 2026.
Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.
Healthcare context
#277 of 440 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #275SCND SCIENTIFIC INDUSTRIES, INC.37.4 out of 100, No moatNo moat
- #276HBIO HARVARD BIOSCIENCE, INC.37.1 out of 100, No moatNo moat
- #278ORMP ORAMED PHARMACEUTICALS INC.36.8 out of 100, No moatNo moat
- #279ECIA ENCISION, INC.36.7 out of 100, No moatNo moat
Compare BAX with its nearest peers →All Healthcare companies on the Index →
Common questions about BAX
- Does BAXTER INTERNATIONAL INC have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores BAXTER INTERNATIONAL INC (BAX) 36.9 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 61, returns on capital 27, balance-sheet safety 0, capital discipline 53.
- How has BAX's Moat Score changed over time?
- The record logs 3 readings since Jul 17, 2026; the latest reads 36.9 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.